埃林扎内坦:一种III期疗法,用于患有血管运动症状的绝经后患者
Jenifer Sassarini1, Richard A Anderson2
1School of Medicine, Dentistry & Nursing, University of Glasgow, Glasgow, UK.
埃林扎涅坦 (Elinzanetant) 是一种有前途的非激素治疗疗法,用于治疗更年期的血管运动症状 (VMS). 这种神经素受体对抗剂显示出快速有效的缓解,解决了对安全VMS疗法的重大未满足需求.
科学领域:
- 神经内分泌学神经内分泌学
- 药理学 药理学是指药理学的学科.
- 妇女健康 妇女健康
背景情况:
- 血管运动症状 (VMS) 在绝经期间显著影响女性的生活质量.
- 激素替代疗法虽然有效,但有相关的风险和禁忌.
- 非常需要一种安全有效的非激素治疗VMS.
研究的目的:
- 调查elinzanetant,一个双NK1和NK3受体抗剂,用于治疗更年期VMS.
- 评估elinzanetant作为非激素VMS治疗的疗效和安全性.
主要方法:
- 在两个临床试验中对绝经期VMS进行了研究Elinzanetant.
- 探索了神经素 (NK) 1和NK3受体的双重对抗性.
- 通过VMS减轻和改善生活质量来评估有效性.
主要成果:
- 埃林扎涅坦在缓解VMS方面表现出迅速发病和剂量依赖的疗效.
- 在长达12周的时间内,人们观察到生活质量的显著改善.
- 目前正在进行更广泛的患者群体的III期试验.
结论:
- 埃林扎涅坦是绝经期VMS的一个有前途的非激素治疗选择.
- 这种药物表现出迅速发作和高效,解决了严重的未满足的医疗需求.
- 目前正在进行的III期试验将进一步探索elazinetant在不同患者群体中的潜力.
更多相关视频
07:20Author Spotlight: Integrating Traditional Chinese Medicine with Modern Pharmacology and Genomics for Assessing Postmenopausal Osteoporosis in Mice
Published on: August 23, 2024
05:36Herbs-Partitioned Moxibustion on the Navel in a Rat Model of Primary Dysmenorrhea with Cold Coagulation and Blood Stasis
Published on: October 4, 2024
相关概念视频
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Menopause
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
